Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2025 Feb 17

PMID 39959643

Authors

Miao Miao

Jiong Yan

Yujin Sun

Jia Liu

Shun Guo

Affiliations

Soon will be listed here.

Abstract

Research into the pathogenesis of inflammatory skin diseases, including dermatitis and psoriasis, has yielded significant advancements in the last decades. The identification of age, gender, and genetic factors contributing to these complex conditions has been pivotal in developing novel pharmacological and technological treatments. This review delves into the molecular underpinnings of psoriasis, examining current therapies and promising investigational agents. We highlight the potential of nanotechnology to enhance drug delivery to affected skin areas, with microneedles emerging as a promising platform for psoriasis and other chronic inflammatory skin diseases.

References

Zhao Z, Chen Y, Shi Y . Microneedles: a potential strategy in transdermal delivery and application in the management of psoriasis. RSC Adv. 2022; 10(24):14040-14049. PMC: 9052076. DOI: 10.1039/d0ra00735h. View

Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A . Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019; 181(1):88-95. DOI: 10.1111/bjd.17628. View

Weinstein G, Koo J, Krueger G, Lebwohl M, Lowe N, Menter M . Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003; 48(5):760-7. DOI: 10.1067/mjd.2003.103. View

Onoufriadis A, Simpson M, Pink A, Di Meglio P, Smith C, Pullabhatla V . Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011; 89(3):432-7. PMC: 3169817. DOI: 10.1016/j.ajhg.2011.07.022. View

Papp K, Leonardi C, Menter A, Ortonne J, Krueger J, Kricorian G . Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366(13):1181-9. DOI: 10.1056/NEJMoa1109017. View

Perrone V, Sangiorgi D, Buda S, Degli Esposti L . Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units. Clinicoecon Outcomes Res. 2017; 9:181-188. PMC: 5345983. DOI: 10.2147/CEOR.S126975. View

Kim W, Jerome D, Yeung J . Diagnosis and management of psoriasis. Can Fam Physician. 2017; 63(4):278-285. PMC: 5389757. View

Souto E, Doktorovova S . Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol. 2009; 464:105-29. DOI: 10.1016/S0076-6879(09)64006-4. View

Pinzon M, Garcia O, Villa C . The influence of Aloe vera gel incorporation on the physicochemical and mechanical properties of banana starch-chitosan edible films. J Sci Food Agric. 2018; 98(11):4042-4049. DOI: 10.1002/jsfa.8915. View

10.

Kumar R, Dogra S, Amarji B, Singh B, Kumar S, Sharma . Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2016; 152(7):807-15. DOI: 10.1001/jamadermatol.2016.0859. View

11.

Ainbinder D, Paolino D, Fresta M, Touitou E . Drug delivery applications with ethosomes. J Biomed Nanotechnol. 2011; 6(5):558-68. DOI: 10.1166/jbn.2010.1152. View

12.

Tuckey R, Li W, Shehabi H, Janjetovic Z, Nguyen M, Kim T . Production of 22-hydroxy metabolites of vitamin d3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells. Drug Metab Dispos. 2011; 39(9):1577-88. PMC: 3164270. DOI: 10.1124/dmd.111.040071. View

13.

Iannone L, Bennardo L, Palleria C, Roberti R, De Sarro C, Naturale M . Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS One. 2020; 15(11):e0241575. PMC: 7608898. DOI: 10.1371/journal.pone.0241575. View

14.

Boutet M, Nerviani A, Gallo Afflitto G, Pitzalis C . Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018; 19(2). PMC: 5855752. DOI: 10.3390/ijms19020530. View

15.

Hengge U, Ruzicka T, Schwartz R, Cork M . Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2005; 54(1):1-15. DOI: 10.1016/j.jaad.2005.01.010. View

16.

Wadhwa B, Relhan V, Goel K, Kochhar A, Garg V . Vitamin D and skin diseases: A review. Indian J Dermatol Venereol Leprol. 2015; 81(4):344-55. DOI: 10.4103/0378-6323.159928. View

17.

Johnston A, Xing X, Wolterink L, Barnes D, Yin Z, Reingold L . IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017; 140(1):109-120. PMC: 5494022. DOI: 10.1016/j.jaci.2016.08.056. View

18.

Berends M, Driessen R, Langewouters A, Boezeman J, van de Kerkhof P, de Jong E . Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat. 2007; 18(2):76-83. DOI: 10.1080/09546630601121086. View

19.

Giustina A, Bouillon R, Binkley N, Sempos C, Adler R, Bollerslev J . Controversies in Vitamin D: A Statement From the Third International Conference. JBMR Plus. 2020; 4(12):e10417. PMC: 7745884. DOI: 10.1002/jbm4.10417. View

20.

Goyal A, Dey A, Chaturvedi A, Elnabawi Y, Aberra T, Chung J . Chronic Stress-Related Neural Activity Associates With Subclinical Cardiovascular Disease in Psoriasis: A Prospective Cohort Study. JACC Cardiovasc Imaging. 2018; 13(2 Pt 1):465-477. PMC: 6506409. DOI: 10.1016/j.jcmg.2018.08.038. View